Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma

被引:8
|
作者
Wu, Yu-Peng [1 ]
Lin, Yun-Zhi [1 ]
Lin, Min-Yi [1 ]
Lin, Ting-Ting [1 ]
Chen, Shao-Hao [1 ]
Wei, Yong [1 ]
Zheng, Qing-Shui [1 ]
Xue, Xue-Yi [1 ]
Xu, Ning [1 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Urol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China
来源
TUMORI JOURNAL | 2018年 / 104卷 / 06期
关键词
Bladder cancer recurrence survival; Nephroureterectomy; SEER; Segmental ureterectomy; Upper-tract urothelial carcinoma; UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; RADICAL NEPHROURETERECTOMY; INTRAVESICAL RECURRENCE; SEGMENTAL URETERECTOMY; SURGICAL-MANAGEMENT; OUTCOMES; EPIDEMIOLOGY; SURVEILLANCE; GUIDELINES;
D O I
10.5301/tj.5000705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC). Methods: We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS. Results: In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016). Conclusions: Use of Su should be more selective for high-grade tumors, as it correlates with shorter BCRS. Tumors located in the ureter are associated with shorter BCRS than those located in the renal pelvis.
引用
收藏
页码:451 / 458
页数:8
相关论文
共 50 条
  • [21] Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance
    Azemar, Marie-Dominique
    Comperat, Eva
    Richard, Francois
    Cussenot, Olivier
    Roupret, Morgan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) : 130 - 136
  • [22] Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
    Mertens, Laura S.
    Sharma, Vidit
    Matin, Surena F.
    Boorjian, Stephen A.
    Thompson, R. Houston
    Van Rhijn, Bas W. G.
    Masson-Lecomte, Alexandra
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 49 : 60 - 66
  • [23] Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration
    Fradet, Vincent
    Mauermann, Julian
    Kassouf, Wassim
    Rendon, Ricardo
    Jacobsen, Niels
    Fairey, Adrian
    Izawa, Jonathan
    Kapoor, Anil
    Black, Peter
    Tanguay, Simon
    Chin, Joseph
    So, Alan
    Lattouf, Jean-Baptiste
    Bell, David
    Saad, Fred
    Sheyegan, Bobby
    Drachenberg, Darren
    Cagiannos, Ilias
    Lacombe, Louis
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (06) : 839 - 845
  • [24] Genomic analysis of same-patient metachronous upper-tract and bladder urothelial carcinoma
    Petros, Firas G.
    Qi, Yuan
    Choi, Woonyoung
    Li, Roger
    Su, Xiaoping
    Guo, Charles
    Dinney, Colin P. N.
    McConkey, David
    Matin, Surena F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma
    Tai, Yi-Sheng
    Chen, Chung-Hsin
    Huang, Chao-Yuan
    Tai, Huai-Chin
    Wang, Sho-Mon
    Pu, Yeong-Shiau
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 (03) : 307 - 314
  • [26] GENOMIC ANALYSIS OF SAME-PATIENT METACHRONOUS UPPER-TRACT AND BLADDER UROTHELIAL CARCINOMA
    Petros, Firas
    Qi, Yuan
    Choi, Woonyoung
    Li, Roger
    Su, Xiaoping
    Guo, Charles
    Dinney, Colin
    McConkey, David
    Matin, Surena
    JOURNAL OF UROLOGY, 2018, 199 (04): : E215 - E216
  • [27] Complex Percutaneous Resections for Upper-Tract Urothelial Carcinoma
    Irwin, Brian H.
    Berger, Andre K.
    Brandina, Ricardo
    Stein, Robert
    Desai, Mihir M.
    JOURNAL OF ENDOUROLOGY, 2010, 24 (03) : 367 - 370
  • [28] Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome
    Donahue, Timothy E.
    Bagrodia, Aditya
    Audenet, Francois
    Donoghue, Mark T. A.
    Cha, Eugene K.
    Sfakianos, John P.
    Sperling, Dahlia
    Al-Ahmadie, Hikmat
    Clendenning, Mark
    Rosty, Christophe
    Buchanan, Daniel D.
    Jenkins, Mark
    Hopper, John
    Winship, Ingrid
    Templeton, Allyson S.
    Walsh, Michael F.
    Stadler, Zsofia K.
    Iyer, Gopa
    Taylor, Barry
    Coleman, Jonathan
    Lindor, Noralane M.
    Solit, David B.
    Bochner, Bernard H.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 13
  • [29] Kidney sparing surgery for upper-tract urothelial carcinoma
    Raman, Jay D.
    MINERVA UROLOGICA E NEFROLOGICA, 2016, 68 (04) : 359 - 371
  • [30] Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer
    Scilipoti, Pietro
    Moschini, Marco
    de Angelis, Mario
    Longoni, Mattia
    Afferi, Luca
    Lonati, Chiara
    Zaurito, Paolo
    Pichler, Renate
    Necchi, Andrea
    Montorsi, Francesco
    Briganti, Alberto
    Mari, Andrea
    Krajewski, Wojciech
    Laukthina, Ekaterina
    Pradere, Benjamin
    Del Giudice, Francesco
    Mertens, Laura
    Gallioli, Andrea
    Soria, Francesco
    Gontero, Paolo
    Albisinni, Simone
    Shariat, Shahrokh F.
    Carando, Roberto
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)